The National Cancer Institute approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10347
A Phase I Study with an Expansion Cohort of Duvelisib and Nivolumab in Mycosis Fungoides (MF) and SÈzary Syndrome (SS)
Yale University Cancer Center LAO
Mehta-Shah, Neha
(314) 747-7402
Phase I – 10450
A Phase 1b Trial of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Ohio State University Comprehensive Cancer Center LAO
Chauhan, Aman
(504) 278-0134
Phase II – A051902
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Alliance for Clinical Trials in Oncology
Mehta-Shah, Neha
(314) 747-7955
Phase III – ANHL1931
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Children’s Oncology Group
Roth, Lisa Giulino
(212) 746-3400
Phase III – EAA171
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
ECOG-ACRIN Cancer Research Group
Kumar, Shaji K.
(507) 284-5096
Phase Other – AMC-113
Observational Cohort Study of People Living with HIV Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies
AIDS Malignancy Consortium
Barta, Stefan Klaus
(215) 615-6506
